{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:22:31Z","timestamp":1791332551518,"version":"4.3.1"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T00:00:00Z","timestamp":1405987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s11883-014-0437-x","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T07:40:37Z","timestamp":1405928437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Congenital Lipodystrophies and Dyslipidemias"],"prefix":"10.1007","volume":"16","author":[{"given":"Xavier","family":"Prieur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Le May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyne","family":"Magr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"437_CR1","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313\u201325. This is a very comprehensive review in terms of clinical classification of the different lipodystrophic syndromes.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/JOE-10-0272","volume":"207","author":"I Huang-Doran","year":"2010","unstructured":"Huang-Doran I, Sleigh A, Rochford JJ, O\u2019Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol. 2010;207:245\u201355.","journal-title":"J Endocrinol"},{"key":"437_CR3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s11892-013-0431-7","volume":"13","author":"C Vatier","year":"2013","unstructured":"Vatier C, Bidault G, Briand N, Gu\u00e9nantin AC, Teyssi\u00e8res L, Lascols O, et al. What the genetics of lipodystrophy can teach us about insulin resistance and diabetes. Curr Diabetes Rep. 2013;13:757\u201367.","journal-title":"Curr Diabetes Rep"},{"key":"437_CR4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ando.2012.04.010","volume":"73","author":"MC Vantyghem","year":"2012","unstructured":"Vantyghem MC, Balavoine AS, Douillard C, Defrance F, Dieudonne L, Mouton F, et al. How to diagnose a lipodystrophy syndrome. Ann Endocrinol (Paris). 2012;73:170\u201389.","journal-title":"Ann Endocrinol (Paris)"},{"key":"437_CR5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1651-2227.1996.tb14262.x","volume":"413","author":"M Seip","year":"1996","unstructured":"Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl. 1996;413:2\u201328.","journal-title":"Acta Paediatr Suppl"},{"key":"437_CR6","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","volume":"87","author":"WA Haque","year":"2002","unstructured":"Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87:2395\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR7","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1210\/jc.2009-1824","volume":"95","author":"B Antuna-Puente","year":"2010","unstructured":"Antuna-Puente B, Boutet E, Vigouroux C, Lascols O, Slama L, Caron-Debarle M, et al. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-O-acyltransferase-2 deficiency. J Clin Endocrinol Metab. 2010;95:1463\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR8","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1210\/jcem.84.9.6103","volume":"84","author":"A Garg","year":"1999","unstructured":"Garg A, Wilson R, Barnes R, Arioglu E, Zaidi Z, Gurakan F, et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab. 1999;84:3390\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng880","volume":"31","author":"AK Agarwal","year":"2002","unstructured":"Agarwal AK, Arioglu E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet. 2002;31:21\u20133.","journal-title":"Nat Genet"},{"key":"437_CR10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ng585","volume":"28","author":"J Magr\u00e9","year":"2001","unstructured":"Magr\u00e9 J, Del\u00e9pine M, Khallouf E, Gedde-Dahl TJ, Van Maldergem L, Sobel E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28:365\u201370.","journal-title":"Nat Genet"},{"key":"437_CR11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2337\/diabetes.52.6.1573","volume":"52","author":"J Magr\u00e9","year":"2003","unstructured":"Magr\u00e9 J, Del\u00e9pine M, Van Maldergem L, Robert JJ, Maassen JA, Meier M, et al. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes. 2003;52:1573\u20138.","journal-title":"Diabetes"},{"key":"437_CR12","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1210\/jc.2007-1328","volume":"93","author":"CA Kim","year":"2008","unstructured":"Kim CA, Del\u00e9pine M, Boutet E, El Mourabit H, Le Lay S, Meier M, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93:1129\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"437_CR13","doi-asserted-by":"crossref","first-page":"e1000874","DOI":"10.1371\/journal.pgen.1000874","volume":"6","author":"A Rajab","year":"2010","unstructured":"Rajab A, Straub V, McCann LJ, Seelow D, Varon R, Barresi R, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 2010;6(3):e1000874.","journal-title":"PLoS Genet"},{"key":"437_CR14","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1172\/JCI38660","volume":"119","author":"YK Hayashi","year":"2009","unstructured":"Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, Mitsuhashi S, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest. 2009;119:2623\u201333.","journal-title":"J Clin Invest"},{"key":"437_CR15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1750-1172-8-119","volume":"8","author":"B Knebel","year":"2013","unstructured":"Knebel B, Kotzka J, Lehr S, Hartwig S, Avci H, Jacob S, et al. A mutation in the c-fos gene associated with congenital generalized lipodystrophy. Orphanet J Rare Dis. 2013;8:119.","journal-title":"Orphanet J Rare Dis"},{"key":"437_CR16","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220\u201334.","journal-title":"N Engl J Med"},{"key":"437_CR17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ng0398-292","volume":"18","author":"JM Peters","year":"1998","unstructured":"Peters JM, Barnes R, Bennett L, Gitomer WM, Bowcock AM, Garg A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat Genet. 1998;18:292\u20135.","journal-title":"Nat Genet"},{"key":"437_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/72807","volume":"24","author":"S Shackleton","year":"2000","unstructured":"Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, et al. LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy. Nat Genet. 2000;24:153\u20136.","journal-title":"Nat Genet"},{"key":"437_CR19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/hmg\/9.1.109","volume":"9","author":"H Cao","year":"2000","unstructured":"Cao H, Hegele RA. Nuclear lamin A\/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000;9:109\u201312.","journal-title":"Hum Mol Genet"},{"key":"437_CR20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/302836","volume":"66","author":"RA Speckman","year":"2000","unstructured":"Speckman RA, Garg A, Du F, Bennett L, Veile R, Arioglu E, et al. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A\/C. Am J Hum Genet. 2000;66:1192\u20138.","journal-title":"Am J Hum Genet"},{"key":"437_CR21","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","volume":"402","author":"I Barroso","year":"1999","unstructured":"Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, et al. Dominant negative mutations in human PPAR\u03b3 associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880\u20133.","journal-title":"Nature"},{"key":"437_CR22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.1096706","volume":"304","author":"S George","year":"2004","unstructured":"George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004;304:1325\u20138.","journal-title":"Science"},{"key":"437_CR23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/emmm.200900037","volume":"1","author":"O Rubio-Cabezas","year":"2009","unstructured":"Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med. 2009;1:280\u20137.","journal-title":"EMBO Mol Med"},{"key":"437_CR24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1007487","volume":"364","author":"S Gandotra","year":"2011","unstructured":"Gandotra S, Le Dour C, Bottomley W, Cervera P, Giral P, Reznik Y, et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med. 2011;364:740\u20138.","journal-title":"N Engl J Med"},{"key":"437_CR25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/jmg.39.10.722","volume":"39","author":"L Maldergem Van","year":"2002","unstructured":"Van Maldergem L, Magr\u00e9 J, Gedde-DahlJr T, Khallouf E, Del\u00e9pine M, Trygstad O, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet. 2002;39:722\u201333.","journal-title":"J Med Genet"},{"key":"437_CR26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","volume":"49","author":"M Adiels","year":"2006","unstructured":"Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755\u201365.","journal-title":"Diabetologia"},{"key":"437_CR27","first-page":"20","volume":"14","author":"M Beylot","year":"1988","unstructured":"Beylot M, Sautot G, Laville M, Cohen R. Metabolic studies in lipoatrophic diabetes: mechanism of hyperglycemia and evidence of resistance to insulin of lipid metabolism. Diabete Metab. 1988;14:20\u20134.","journal-title":"Diabete Metab"},{"key":"437_CR28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.2004.02103.x","volume":"61","author":"BL Wajchenberg","year":"2004","unstructured":"Wajchenberg BL, Am\u00e2ncio RF, Santomauro AT, Maranh\u00e3o RC. Metabolism of chylomicrons in patients with congenital lipoatrophic diabetes: a study with emulsion models of chylomicrons. Clin Endocrinol (Oxf). 2004;61:347\u201352.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"437_CR29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00445766","volume":"127","author":"S Kodama","year":"1978","unstructured":"Kodama S, Kasuga M, Seki A, Ninomiya M, Sakurai T, Morishita Y, et al. Congenital generalized lipodystrophy with insulin-resistant diabetes. Eur J Pediatr. 1978;127:111\u20139.","journal-title":"Eur J Pediatr"},{"key":"437_CR30","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1210\/jcem-39-6-1030","volume":"39","author":"C Naito","year":"1974","unstructured":"Naito C, Togawa K. A possible role of circulating lipoprotein-triglycerides in the increase in concentration of free fatty acids and in insulin resistance in \u201ctotal\u201d lipodystrophy. J Clin Endocrinol Metab. 1974;39:1030\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1055\/s-2007-1010891","volume":"20","author":"G Enzi","year":"1988","unstructured":"Enzi G, Digito M, Baldo-Enzi G, Cominacini L, Dodi G, Carraro R, et al. Lipid metabolism in lipoatrophic diabetes. Horm Metab Res. 1988;20:587\u201391.","journal-title":"Horm Metab Res"},{"key":"437_CR32","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1210\/jc.2007-2356","volume":"93","author":"GD Tan","year":"2008","unstructured":"Tan GD, Savage DB, Fielding BA, Collins J, Hodson L, Humphreys SM, et al. Fatty acid metabolism in patients with PPAR\u03b3 mutations. J Clin Endocrinol Metab. 2008;93:4462\u201370.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR33","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1210\/jc.2004-1494","volume":"90","author":"DB Savage","year":"2005","unstructured":"Savage DB, Murgatroyd PR, Chatterjee VK, O\u2019Rahilly S. Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. J Clin Endocrinol Metab. 2005;90:1446\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/jc.2008-1703","volume":"94","author":"DB Savage","year":"2009","unstructured":"Savage DB, Semple RK, Clatworthy MR, Lyons PA, Morgan BP, Cochran EK, et al. Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab. 2009;94:10\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR35","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1101\/gad.7.7b.1318","volume":"7","author":"R Ross","year":"1993","unstructured":"Ross R, Graves A, Spiegelman M. Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity. Genes Dev. 1993;7:1318\u201324.","journal-title":"Genes Dev"},{"key":"437_CR36","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1101\/gad.12.20.3182","volume":"12","author":"I Shimomura","year":"1998","unstructured":"Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 1998;12:3182\u201394.","journal-title":"Genes Dev"},{"key":"437_CR37","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1101\/gad.12.20.3168","volume":"12","author":"J Moitra","year":"1998","unstructured":"Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, et al. Life without white fat: a transgenic mouse. Genes Dev. 1998;12:3168\u201381.","journal-title":"Genes Dev"},{"key":"437_CR38","doi-asserted-by":"crossref","first-page":"12532","DOI":"10.1073\/pnas.211416898","volume":"98","author":"HG Linhart","year":"2001","unstructured":"Linhart HG, Ishimura-Oka K, DeMayo F, Kibe T, Repka D, Poindexter B, et al. C\/EBP\u03b1 is required for differentiation of white, but not brown, adipose tissue. Proc Natl Acad Sci U S A. 2001;98:12532\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"437_CR39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI7901","volume":"105","author":"O Gavrilova","year":"2000","unstructured":"Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105:271\u20138.","journal-title":"J Clin Invest"},{"key":"437_CR40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","volume":"401","author":"I Shimomura","year":"1999","unstructured":"Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401:73\u20136.","journal-title":"Nature"},{"key":"437_CR41","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.2337\/diabetes.50.6.1440","volume":"50","author":"K Ebihara","year":"2001","unstructured":"Ebihara K, Ogawa Y, Masuzaki H, Shintani M, Miyanaga F, Aizawa-Abe M, et al. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes. 2001;50:1440\u20138.","journal-title":"Diabetes"},{"key":"437_CR42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1097-2765(00)80211-7","volume":"4","author":"ED Rosen","year":"1999","unstructured":"Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, et al. PPAR\u03b3 is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4:611\u20137.","journal-title":"Mol Cell"},{"key":"437_CR43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1097-2765(00)80209-9","volume":"4","author":"Y Barak","year":"1999","unstructured":"Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, et al. PPAR\u03b3 is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585\u201395.","journal-title":"Mol Cell"},{"key":"437_CR44","doi-asserted-by":"crossref","first-page":"15712","DOI":"10.1073\/pnas.2536828100","volume":"100","author":"W He","year":"2003","unstructured":"He W, Barak Y, Hevener A, Olson P, Liao D, Le J, et al. Adipose-specific peroxisome proliferator-activated receptor \u03b3 knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A. 2003;100:15712\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"437_CR45","doi-asserted-by":"crossref","first-page":"18656","DOI":"10.1073\/pnas.1314863110","volume":"110","author":"F Wang","year":"2013","unstructured":"Wang F, Mullican SE, DiSpirito JR, Peed LC, Lazar MA. Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPAR\u03b3. Proc Natl Acad Sci U S A. 2013;110:18656\u201361. Complete deletion of PPAR\u03b3 in mature adipocytes has been quite a challenge during the last 10 years. This article provides important insight into the role of PPAR\u03b3 after the initiation of adipogenesis.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"437_CR46","doi-asserted-by":"crossref","first-page":"8635","DOI":"10.1074\/jbc.M110970200","volume":"277","author":"B Razani","year":"2002","unstructured":"Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem. 2002;277:8635\u201347.","journal-title":"J Biol Chem"},{"key":"437_CR47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0092-8674(92)90143-Z","volume":"68","author":"KG Rothberg","year":"1992","unstructured":"Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell. 1992;68:673\u201382.","journal-title":"Cell"},{"key":"437_CR48","doi-asserted-by":"crossref","first-page":"C222","DOI":"10.1152\/ajpcell.00006.2003","volume":"285","author":"AW Cohen","year":"2003","unstructured":"Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. 2003;285:C222\u201335.","journal-title":"Am J Physiol Cell Physiol"},{"key":"437_CR49","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbalip.2008.10.008","volume":"1791","author":"S Lay Le","year":"2009","unstructured":"Le Lay S, Blouin CM, Hajduch E, Dugail I. Filling up adipocytes with lipids. Lessons from caveolin-1 deficiency. Biochim Biophys Acta. 2009;1791:514\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"437_CR50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1600-0854.2006.00406.x","volume":"7","author":"S Lay Le","year":"2006","unstructured":"Le Lay S, Hajduch E, Lindsay MR, Le Liepvre X, Thiele C, Ferre P, et al. Cholesterol-induced caveolin targeting to lipid droplets in adipocytes: a role for caveolar endocytosis. Traffic. 2006;7:549\u201361.","journal-title":"Traffic"},{"key":"437_CR51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1194\/jlr.M001016","volume":"51","author":"CM Blouin","year":"2010","unstructured":"Blouin CM, Le Lay S, Eberl A, Kofeler HC, Guerrera IC, Klein C, et al. Lipid droplet analysis in caveolin-deficient adipocytes: alterations in surface phospholipid composition and maturation defects. J Lipid Res. 2010;51:945\u201356.","journal-title":"J Lipid Res"},{"key":"437_CR52","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4161\/auto.6.6.12574","volume":"6","author":"S Lay Le","year":"2010","unstructured":"Le Lay S, Briand N, Blouin CM, Chateau D, Prado C, Lasnier F, et al. The lipoatrophic caveolin-1 deficient mouse model reveals autophagy in mature adipocytes. Autophagy. 2010;6:754\u201363.","journal-title":"Autophagy"},{"key":"437_CR53","doi-asserted-by":"crossref","first-page":"e46242","DOI":"10.1371\/journal.pone.0046242","volume":"7","author":"S Martin","year":"2012","unstructured":"Martin S, Fernandez-Rojo MA, Stanley AC, Bastiani M, Okano S, Nixon SJ, et al. Caveolin-1 deficiency leads to increased susceptibility to cell death and fibrosis in white adipose tissue: characterization of a lipodystrophic model. PLoS One. 2012;7:e46242.","journal-title":"PLoS One"},{"key":"437_CR54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/01.ATV.0000101182.89118.E5","volume":"24","author":"PG Frank","year":"2004","unstructured":"Frank PG, Lee H, Park DS, Tandon NN, Scherer PE, Lisanti MP. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:98\u2013105.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"437_CR55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cmet.2009.01.002","volume":"9","author":"VA Cort\u00e9s","year":"2009","unstructured":"Cort\u00e9s VA, Curtis DE, Sukumaran S, Shao X, Parameswara V, Rashid S, et al. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab. 2009;9:165\u201376.","journal-title":"Cell Metab"},{"key":"437_CR56","doi-asserted-by":"crossref","unstructured":"Agarwal AK, Sukumaran S, Cort\u00e9s VA, Tunison K, Mizrachi D, Sankella S, et al. Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2-\/- gene lipodystrophic mice. J Biol Chem. 2011;286:37676\u201391. In this study, the authors demontrate that liver re-expression of AGPAT2 is not sufficient to rescue the severe liver steatosis phenotype.","DOI":"10.1074\/jbc.M111.250449"},{"key":"437_CR57","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.2337\/db12-0004","volume":"61","author":"AR Subauste","year":"2012","unstructured":"Subauste AR, Das AK, Li X, Elliott BG, Elliot B, Evans C, et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes. 2012;61:2922\u201331.","journal-title":"Diabetes"},{"key":"437_CR58","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1074\/jbc.M509612200","volume":"281","author":"SE Gale","year":"2006","unstructured":"Gale SE, Frolov A, Han X, Bickel PE, Cao L, Bowcock A, et al. A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation. J Biol Chem. 2006;281:11082\u20139.","journal-title":"J Biol Chem"},{"key":"437_CR59","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-2275(20)32011-3","volume":"41","author":"K Reue","year":"2000","unstructured":"Reue K, Xu P, Wang XP, Slavin BG. Adipose tissue deficiency, glucose intolerance, and increased atherosclerosis result from mutation in the mouse fatty liver dystrophy (fld) gene. J Lipid Res. 2000;41:1067\u201376.","journal-title":"J Lipid Res"},{"key":"437_CR60","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1016\/S0021-9258(18)83141-6","volume":"264","author":"CA Langner","year":"1989","unstructured":"Langner CA, Birkenmeier EH, Ben-Zeev O, Schotz MC, Sweet HO, Davisson MT, et al. The fatty liver dystrophy (fld) mutation. A new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specific defects in lipoprotein lipase and hepatic lipase activities. J Biol Chem. 1989;264:7994\u20138003.","journal-title":"J Biol Chem"},{"key":"437_CR61","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1074\/jbc.M610745200","volume":"282","author":"J Donkor","year":"2007","unstructured":"Donkor J, Sariahmetoglu M, Dewald J, Brindley DN, Reue K. Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J Biol Chem. 2007;282:3450\u20137.","journal-title":"J Biol Chem"},{"key":"437_CR62","doi-asserted-by":"crossref","first-page":"29558","DOI":"10.1074\/jbc.M403506200","volume":"279","author":"J Phan","year":"2004","unstructured":"Phan J, P\u00e9terfy M, Reue K. Lipin expression preceding peroxisome proliferator-activated receptor-\u03b3 is critical for adipogenesis in vivo and in vitro. J Biol Chem. 2004;279:29558\u201364.","journal-title":"J Biol Chem"},{"key":"437_CR63","doi-asserted-by":"crossref","unstructured":"Nadra K, M\u00e9dard JJ, Mul JD, Han GS, Gr\u00e8s S, Pende M, et al. Cell autonomous lipin 1 function is essential for development and maintenance of white and brown adipose tissue. Mol Cell Biol. 2012;32:4794\u2013810. In this study, the authors demonstrate for the first time that adipocyte-specific deletion of lipin 1 is responsible for the lipodystrophic phenotype in Fld mice. This is a very complete invivo and invitro study.","DOI":"10.1128\/MCB.00512-12"},{"key":"437_CR64","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1161\/ATVBAHA.108.171538","volume":"28","author":"Z Chen","year":"2008","unstructured":"Chen Z, Gropler MC, Norris J, Lawrence JC, Harris TE, Finck BN. Alterations in hepatic metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion. Arterioscler Thromb Vasc Biol. 2008;28:1738\u201344.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"437_CR65","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/hep.26589","volume":"58","author":"M Hu","year":"2013","unstructured":"Hu M, Yin H, Mitra MS, Liang X, Ajmo JM, Nadra K, et al. Hepatic-specific lipin-1 deficiency exacerbates experimental alcohol-induced steatohepatitis in mice. Hepatology. 2013;58:1953\u201363.","journal-title":"Hepatology"},{"key":"437_CR66","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1172\/JCI27794","volume":"116","author":"BN Finck","year":"2006","unstructured":"Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116:615\u201322.","journal-title":"J Clin Invest"},{"key":"437_CR67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1083\/jcb.200711136","volume":"180","author":"W Fei","year":"2008","unstructured":"Fei W, Shui G, Gaeta B, Du X, Kuerschner L, Li P, et al. Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. J Cell Biol. 2008;180:473\u201382.","journal-title":"J Cell Biol"},{"key":"437_CR68","doi-asserted-by":"crossref","first-page":"20890","DOI":"10.1073\/pnas.0704154104","volume":"104","author":"KM Szymanski","year":"2007","unstructured":"Szymanski KM, Binns D, Bartz R, Grishin NV, Li WP, Agarwal AK, et al. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc Natl Acad Sci U S A. 2007;104:20890\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"437_CR69","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.biochi.2009.01.011","volume":"91","author":"E Boutet","year":"2009","unstructured":"Boutet E, El Mourabit H, Prot M, Nemani M, Khallouf E, Colard O, et al. Seipin deficiency alters fatty acid \u03949 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy. Biochimie. 2009;91:796\u2013803.","journal-title":"Biochimie"},{"key":"437_CR70","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1194\/jlr.R023754","volume":"53","author":"BR Cartwright","year":"2012","unstructured":"Cartwright BR, Goodman JM. Seipin: from human disease to molecular mechanism. J Lipid Res. 2012;53:1042\u201355.","journal-title":"J Lipid Res"},{"key":"437_CR71","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2337\/db08-0184","volume":"57","author":"VA Payne","year":"2008","unstructured":"Payne VA, Grimsey N, Tuthill A, Virtue S, Gray SL, Dalla Nora E, et al. The human lipodystrophy gene BSCL2\/seipin may be essential for normal adipocyte differentiation. Diabetes. 2008;57:2055\u201360.","journal-title":"Diabetes"},{"key":"437_CR72","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1210\/en.2009-0236","volume":"150","author":"W Chen","year":"2009","unstructured":"Chen W, Yechoor VK, Chang BH, Li MV, March KL, Chan L. The human lipodystrophy gene product Berardinelli-Seip congenital lipodystrophy 2\/seipin plays a key role in adipocyte differentiation. Endocrinology. 2009;150:4552\u201361.","journal-title":"Endocrinology"},{"key":"437_CR73","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/MCB.06465-11","volume":"32","author":"W Chen","year":"2012","unstructured":"Chen W, Chang B, Saha P, Hartig SM, Li L, Reddy VT, et al. Berardinelli-Seip congenital lipodystrophy 2\/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation. Mol Cell Biol. 2012;32:1099\u2013111.","journal-title":"Mol Cell Biol"},{"key":"437_CR74","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00125-013-2926-9","volume":"56","author":"X Prieur","year":"2013","unstructured":"Prieur X, Dollet L, Takahashi M, Nemani M, Pillot B, Le May C, et al. Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2\/seipin-deficient mice. Diabetologia. 2013;56:1813\u201325.","journal-title":"Diabetologia"},{"key":"437_CR75","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1093\/hmg\/ddr205","volume":"20","author":"X Cui","year":"2011","unstructured":"Cui X, Wang Y, Tang Y, Liu Y, Zhao L, Deng J, et al. Seipin ablation in mice results in severe generalized lipodystrophy. Hum Mol Genet. 2011;20:3022\u201330.","journal-title":"Hum Mol Genet"},{"key":"437_CR76","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.biochi.2013.06.022","volume":"96","author":"L Dollet","year":"2014","unstructured":"Dollet L, Magr\u00e9 J, Cariou B, Prieur X. Function of seipin: new insights from Bscl2\/seipin knockout mouse models. Biochimie. 2014;96:166\u201372.","journal-title":"Biochimie"},{"key":"437_CR77","author":"L Liu","year":"2014","unstructured":"Liu L, Jiang Q, Wang X, Zhang Y, Lin RC, Lam SM, et al. Adipose-specific knockout of Seipin\/Bscl2 results in progressive lipodystrophy. Diabetes. 2014. doi: 10.2337\/db13-0729 .","journal-title":"Diabetes"},{"key":"437_CR78","doi-asserted-by":"crossref","first-page":"e1002201","DOI":"10.1371\/journal.pgen.1002201","volume":"7","author":"W Fei","year":"2011","unstructured":"Fei W, Shui G, Zhang Y, Krahmer N, Ferguson C, Kapterian TS, et al. A role for phosphatidic acid in the formation of \u201csupersized\u201d lipid droplets. PLoS Genet. 2011;7:e1002201.","journal-title":"PLoS Genet"},{"key":"437_CR79","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molmet.2012.11.002","volume":"2","author":"MF Sim","year":"2012","unstructured":"Sim MF, Dennis RJ, Aubry EM, Ramanathan N, Sembongi H, Saudek V, et al. The human lipodystrophy protein seipin is an ER membrane adaptor for the adipogenic PA phosphatase lipin 1. Mol Metab. 2012;2:38\u201346.","journal-title":"Mol Metab"},{"key":"437_CR80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","volume":"82","author":"A Misra","year":"2003","unstructured":"Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore). 2003;82:129\u201346.","journal-title":"Medicine (Baltimore)"},{"key":"437_CR81","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/EP13248.CS","volume":"19","author":"Y Handelsman","year":"2013","unstructured":"Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19:107\u201316.","journal-title":"Endocr Pract"},{"key":"437_CR82","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.metabol.2009.02.012","volume":"58","author":"S Tsiodras","year":"2009","unstructured":"Tsiodras S, Poulia KA, Yannakoulia M, Chimienti SN, Wadhwa S, Karchmer AW, et al. Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism. 2009;58:854\u20139.","journal-title":"Metabolism"},{"key":"437_CR83","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"J Bosch","year":"2012","unstructured":"Bosch J, Gerstein HC, Dagenais GR, D\u00edaz R, Dyal L, Jung H, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309\u201318.","journal-title":"N Engl J Med"},{"key":"437_CR84","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med"},{"key":"437_CR85","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849\u201361.","journal-title":"Lancet"},{"key":"437_CR86","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267\u201378.","journal-title":"Lancet"},{"key":"437_CR87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-511X-6-27","volume":"6","author":"KW Johns","year":"2007","unstructured":"Johns KW, Bennett MT, Bondy GP. Are HIV positive patients resistant to statin therapy? Lipids Health Dis. 2007;6:27.","journal-title":"Lipids Health Dis"},{"key":"437_CR88","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/01.aids.0000222072.37749.5a","volume":"20","author":"PW Mallon","year":"2006","unstructured":"Mallon PW, Miller J, Kovacic JC, Kent-Hughes J, Norris R, Samaras K, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men\u2013a randomized, placebo-controlled study. AIDS. 2006;20:1003\u201310.","journal-title":"AIDS"},{"key":"437_CR89","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","volume":"122","author":"B Viollet","year":"2012","unstructured":"Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122:253\u201370.","journal-title":"Clin Sci (Lond)"},{"key":"437_CR90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2334-10-183","volume":"10","author":"SH Sheth","year":"2010","unstructured":"Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis. 2010;10:183.","journal-title":"BMC Infect Dis"},{"key":"437_CR91","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1161\/ATVBAHA.110.216192","volume":"31","author":"JP Wijk van","year":"2011","unstructured":"van Wijk JP, Hoepelman AI, de Koning EJ, Dallinga-Thie G, Rabelink TJ, Cabezas MC. Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arterioscler Thromb Vasc Biol. 2011;31:228\u201333.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"437_CR92","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","volume":"23","author":"B Cariou","year":"2012","unstructured":"Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPAR\u03b3 agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205\u201315.","journal-title":"Trends Endocrinol Metab"},{"key":"437_CR93","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/diabetes.53.8.2169","volume":"53","author":"M Tiikkainen","year":"2004","unstructured":"Tiikkainen M, H\u00e4kkinen AM, Korsheninnikova E, Nyman T, M\u00e4kimattila S, Yki-J\u00e4rvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169\u201376.","journal-title":"Diabetes"},{"key":"437_CR94","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","volume":"87","author":"Y Miyazaki","year":"2002","unstructured":"Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784\u201391.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR95","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1210\/jc.2007-1825","volume":"93","author":"L Juurinen","year":"2008","unstructured":"Juurinen L, Kotronen A, Gran\u00e9r M, Yki-J\u00e4rvinen H. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab. 2008;93:118\u201324.","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR96","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","volume":"133","author":"E Arioglu","year":"2000","unstructured":"Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133:263\u201374.","journal-title":"Ann Intern Med"},{"key":"437_CR97","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1464-5491.2005.01757.x","volume":"22","author":"A L\u00fcdtke","year":"2005","unstructured":"L\u00fcdtke A, Heck K, Genschel J, Mehnert H, Spuler S, Worman HJ, et al. Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone. Diabet Med. 2005;22:1611\u20133.","journal-title":"Diabet Med"},{"key":"437_CR98","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1530\/EJE-08-0272","volume":"159","author":"A Gambineri","year":"2008","unstructured":"Gambineri A, Semple RK, Forlani G, Genghini S, Grassi I, Hyden CS, et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A\/C gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol. 2008;159:347\u201353.","journal-title":"Eur J Endocrinol"},{"key":"437_CR99","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.diabet.2007.04.005","volume":"33","author":"F Moreau","year":"2007","unstructured":"Moreau F, Boullu-Sanchis S, Vigouroux C, Lucescu C, Lascols O, Sapin R, et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab. 2007;33:385\u20139.","journal-title":"Diabetes Metab"},{"key":"437_CR100","doi-asserted-by":"crossref","first-page":"W602","DOI":"10.2214\/AJR.11.8110","volume":"199","author":"PD McLaughlin","year":"2012","unstructured":"McLaughlin PD, Ryan J, Hodnett PA, O\u2019Halloran D, Maher MM. Quantitative whole-body MRI in familial partial lipodystrophy type 2: changes in adipose tissue distribution coincide with biochemical improvement. AJR Am J Roentgenol. 2012;199:W602\u20136.","journal-title":"AJR Am J Roentgenol"},{"key":"437_CR101","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297\u2013307.","journal-title":"N Engl J Med"},{"key":"437_CR102","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1463-1326.2008.00978.x","volume":"10","author":"V Simha","year":"2008","unstructured":"Simha V, Rao S, Garg A. Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety. Diabetes Obes Metab. 2008;10:1275\u20136.","journal-title":"Diabetes Obes Metab"},{"key":"437_CR103","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1464-5491.2010.03052.x","volume":"27","author":"B Victoria","year":"2010","unstructured":"Victoria B, Cabezas-Agricola JM, Gonzalez-Mendez B, Lattanzi G, Del Coco R, Loidi L, et al. Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy. Diabet Med. 2010;27:1178\u201387.","journal-title":"Diabet Med"},{"key":"437_CR104","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","volume":"28","author":"RB Goldberg","year":"2005","unstructured":"Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547\u201354.","journal-title":"Diabetes Care"},{"key":"437_CR105","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u201389.","journal-title":"Lancet"},{"key":"437_CR106","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","volume":"17","author":"JL Chan","year":"2011","unstructured":"Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17:922\u201332.","journal-title":"Endocr Pract"},{"key":"437_CR107","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1530\/EJE-09-1027","volume":"162","author":"J Beltrand","year":"2010","unstructured":"Beltrand J, Lahlou N, Le Charpentier T, Sebag G, Leka S, Polak M, et al. Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. Eur J Endocrinol. 2010;162:1083\u201391.","journal-title":"Eur J Endocrinol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-014-0437-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-014-0437-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-014-0437-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T19:17:52Z","timestamp":1649704672000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-014-0437-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,22]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s11883-014-0437-x","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,22]]},"article-number":"437"}}